The deal for BeiGene's mas­sive new US man­u­fac­tur­ing and R&D site is com­plete, and it plans to pour in 'sev­er­al hun­dred mil­lion dol­lars' soon

Months af­ter an­nounc­ing plans to build a new man­u­fac­tur­ing cam­pus in Hopewell, NJ, BeiGene has closed on the 42-acre site at the Prince­ton West In­no­va­tion Park Tues­day.

The com­pa­ny, which is fo­cused on de­vel­op­ing and com­mer­cial­iz­ing can­cer med­i­cines, an­nounced that it will house man­u­fac­tur­ing and clin­i­cal R&D at the site, in an ef­fort to boost its sup­ply chain.

The first stages of the project will cost “sev­er­al hun­dred mil­lion dol­lars,” and the fa­cil­i­ty will in­clude 400,000 square feet of com­mer­cial stage bi­o­log­ic man­u­fac­tur­ing, along with 16,000 liters of ca­pac­i­ty and clin­i­cal R&D and of­fice space. The con­struc­tion will start in 2022, and wrap up in late-2023 or 2024. An­oth­er 1 mil­lion square feet worth of space leaves the door open for fu­ture ex­pan­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER